Anti-PD-L1 checkpoint inhibitors: Decoding the mystery

July 24, 2019 | City of Hope

An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.

Continue Reading

City of Hope to offer CAR T cell therapy for patients with the most common type of NHL

May 4, 2018 | Letisia Marquez

City of Hope recently announced that it is one of the first treatment centers certified in the United States to administer tisagenlecleucel CAR T cell therapy to adult patients with relapsed or refractory large B cell lymphoma.

First FDA-approved CAR T Therapy for Some Types of ALL to Be Offered at City of Hope

April 13, 2018 | Letisia Marquez

City of Hope recently announced that it is a certified treatment center to administer tisagenlecleucel CAR T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration – to patients.